ANT-GROUP
Ant Group, a global technology provider, today announced its Environmental, Social and Governance (ESG) strategy as part of its latest sustainability report. The ESG strategy, which lays out Ant Group’s sustainable development objectives by 2030, will be implemented across all aspects of the Company’s operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220531006112/en/
Ant Group’s ESG strategy is focused around four pillars: Digital Inclusion, Green and Low-carbon Development, Open Ecosystem, and Technological Innovation. Each of the pillars has a corresponding sustainable development objective by 2030:
- Digital Inclusion: support 100 million small and micro-sized enterprises (SMEs) and serve communities globally
- Green and Low-carbon Development: achieve corporate carbon neutrality and support business partners and the general public to significantly reduce their carbon footprint
- Open Ecosystem: continue to provide a safe, trusted, diversified and open ecosystem to drive common development with partners
- Technological Innovation: continue to invest in core technology research and development to provide world-leading technological products and services
"We believe these are the most important pillars for Ant Group to achieve sustainable growth in a future-facing, responsible, and responsive manner,” wrote Eric Jing, Ant Group’s Chairman and CEO, in the sustainability report. ”This framework will guide Ant Group’s value creation and sustainable development in the future.”
Ant Group formulated its ESG strategy based on a comprehensive assessment of changing macro environment and policy trends, its own development strengths, and inputs from the Company’s stakeholders, including customers, users, employees, partners and governments. The ESG strategy was finalized after extensive management discussions and a detailed Board review.
After solicitating feedback from stakeholders, Ant Group defined 19 material issues for its ESG strategy, ranging from “responsible products and services,” “facilitating industry-wide carbon neutrality,” “cutting-edge technology discovery and R&D” and “transparency & risk management.”
To provide organizational support to effectively implement the ESG strategy, the Company’s Board of Directors has approved the establishment of an ESG sustainable development committee, comprised of a subset of the Board, responsible for decision-making supervision, risk management and policy making. The Company is setting up an advisory committee consisting of internal and external ESG experts to provide input and support. Ant Group has also set up an ESG sustainable development leadership team, led by the CEO and the Chief Sustainability Officer, as well as working groups for each of the 19 ESG material issues.
“Our ESG strategy originated from our own long-term needs and was not a spur-of-the-moment decision. The pursuit of sustainable development has been inherent in every step of our journey and is not designed to cater to short-term trends, but rather a necessary driver to realize our vision to be a good company that will last for at least 102 years,” added Mr. Jing. “A good company is never independently defined. We will listen to the opinions and suggestions from all parties with an open mind and welcome supervision and guidance from all of our stakeholders.”
As part of its “Technological Innovation” pillar, Ant Group has been increasing its R&D investments, which grew at an annual rate of more than 39% for three consecutive years (2018-2021), with total R&D spending in 2021 exceeding RMB 18.8 billion (approx. USD 2.77 billion). These investments enabled the Company to continuously turn technological breakthroughs into innovative, inclusive and reliable products and services to support the digital transformation of industries and better anticipate the evolving needs of an increasingly digital global economy. In 2021, MYbank, an Ant Group associate and an online SME bank, leveraged digital technology to deliver convenient, accessible and responsible collateral-free financing services to 45 million SMEs.
In February 2022, Ant Group was recognized as a Top 100 Global Innovator™ 2022 by Clarivate™ . This prestigious annual list identifies global companies and institutions that contribute new ideas, solve problems and create new economic value.
Since 2017, three years after Ant Group’s establishment, the Company has steadily introduced and advanced its ESG assessment framework and published an annual sustainability report, compiled according to the Global Reporting Initiative standards. These reports, including the latest 2021 edition with the Company’s ESG strategy, can be found on Ant Group’s website (Chinese only for now, English edition will be online in the coming weeks).
About Ant Group
Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220531006112/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release
OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly
Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release
Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit
Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release
New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc
LTIMindtree Wins Two 2025 AWS Partner Awards at AWS re:Invent4.12.2025 13:45:00 CET | Press release
Recognized as Application Modernization Consulting Partner of the Year and Industry Partner of the Year - Travel and Hospitality winner LTIMindtree [NSE: LTIM, BSE: 540005], a leading global technology consulting and digital solutions provider, announced that it received the AWS 2025 Geography and Global Partner Awards, recognizing leaders around the globe who play key roles in helping clients drive innovation and build solutions on Amazon Web Services (AWS). LTIMindtree has been awarded Application Modernization Consulting Partner of the Year (Global) and Industry Partner of the Year - Travel and Hospitality. At the AWS re:Invent 2025 Partner Awards Gala, partners were recognized for their specialization, innovation, and collaboration, and for evolving business models that enable success on AWS while supporting their customers. LTIMindtree was recognized as: The Industry Partner of the Year - Travel and Hospitality: Recognized as a trusted transformation partner in Travel and Hospital
Stafford Establishes Timberland Continuation Fund at USD 1.2 billion4.12.2025 10:53:00 CET | Press release
This marks Stafford’s second timberland fund at over USD 1 Billion in 2025, backed by strong existing investor support and new capital commitments from global institutional investors Stafford Capital Partners (“Stafford”) today announced it has established a USD 1.2 billion continuation vehicle, the Stafford International Timberland Continuation Fund (The Continuation Fund or The Fund), marking a significant milestone in the firm’s strategic management of its timberland holdings. The Continuation Fund is a "roll-up" of three of Stafford’s existing core timberland funds – Stafford International Timberland funds VI, VII and VIII – into a new perpetual fund that will hold 74 high-quality core timberland assets. The fully-deployed portfolio took Stafford seven years to construct and holds interests in over 6.3m acres of commercial timberland in the USA, New Zealand, Australia and Latin America. This includes a number of assets that are seen as key strategic holdings in these regions where
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
